Atrás
63
6
34
Rango del Día
$0.66
$0.66
Rango de 52 Semanas
$0.56
$0.74
Volumen
1,000
Promedio 50D / 200D
$0.61
/
$0.63
Cierre Anterior
$0.66
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Healthcare (627 pares)
| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | 0.7 | 0.3 |
| P/B | 0.1 | 2.9 |
| ROE % | 15.4 | 3.7 |
| Net Margin % | 14.2 | 3.8 |
| Rev Growth 5Y % | 10.6 | 10.0 |
| D/E | 0.2 | 0.2 |
Precio Objetivo de Analistas
No hay cobertura de analistas disponible
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2027 |
$0.00
$0.00 – $0.00
|
120 B | 0 |
| FY2026 |
$0.00
$0.00 – $0.00
|
120 B | 0 |
Puntos Clave
Revenue grew 10.60% annually over 5 years — strong growth
ROE of 15.39% — decent returns on equity
Debt/Equity of 0.17 — conservative balance sheet
Generating 13.02B in free cash flow
P/E of 0.66 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 7.31%
Crecimiento
Revenue Growth (5Y)
10.60%
Revenue (1Y)3.29%
Earnings (1Y)-0.95%
FCF Growth (3Y)2.18%
Calidad
Return on Equity
15.39%
ROIC11.22%
Net Margin14.21%
Op. Margin16.56%
Seguridad
Debt / Equity
0.17
Current Ratio0.98
Interest Coverage51.78
Valoración
P/E Ratio
0.66
P/B Ratio0.10
EV/EBITDA1.17
Dividend Yield0.04%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 3.29% | Revenue Growth (3Y) | 5.11% |
| Earnings Growth (1Y) | -0.95% | Earnings Growth (3Y) | 4.96% |
| Revenue Growth (5Y) | 10.60% | Earnings Growth (5Y) | 18.85% |
| Profitability | |||
| Revenue (TTM) | 111.42B | Net Income (TTM) | 15.84B |
| ROE | 15.39% | ROA | 10.03% |
| Gross Margin | 34.91% | Operating Margin | 16.56% |
| Net Margin | 14.21% | Free Cash Flow (TTM) | 13.02B |
| ROIC | 11.22% | FCF Growth (3Y) | 2.18% |
| Safety | |||
| Debt / Equity | 0.17 | Current Ratio | 0.98 |
| Interest Coverage | 51.78 | Dividend Yield | 0.04% |
| Valuation | |||
| P/E Ratio | 0.66 | P/B Ratio | 0.10 |
| P/S Ratio | 0.09 | PEG Ratio | -19.43 |
| EV/EBITDA | 1.17 | Dividend Yield | 0.04% |
| Market Cap | 10.49B | Enterprise Value | 21.64B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 111.42B | 107.87B | 100.85B | 91.93B | 74.45B |
| Net Income | 15.84B | 15.99B | 14.38B | 12.61B | 7.94B |
| EPS (Diluted) | 1.00 | 1.01 | 0.90 | 0.79 | 0.50 |
| Gross Profit | 38.89B | 39.80B | 37.44B | 33.60B | 24.99B |
| Operating Income | 18.45B | 20.51B | 18.94B | 16.99B | 11.23B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 157.83B | 151.51B | 143.60B | 141.54B | 128.45B |
| Total Liabilities | 47.91B | 47.59B | 44.72B | 47.83B | 40.69B |
| Shareholders' Equity | 105.81B | 100.04B | 95.44B | 89.88B | 83.85B |
| Total Debt | 17.49B | 18.36B | 18.13B | 23.59B | 18.83B |
| Cash & Equivalents | 6.34B | 7.37B | 7.79B | 12.67B | 10.93B |
| Current Assets | 23.09B | 23.66B | 23.55B | 27.80B | 24.40B |
| Current Liabilities | 23.61B | 22.01B | 18.43B | 20.62B | 15.86B |
Puntuaciones de Estrategias
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
#113 of 827
#593 of 670
#278 of 709
Actividad Reciente
Entró
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entró
Contrarian Investing (David Dreman)
Mar 24, 2026
Entró
Defensive Investing (Benjamin Graham)
Mar 24, 2026